Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort

Abstract

In this single-institution cohort of patients, OMD was as a strong prognostic factor in patients with metastatic GIST. Patients with OMD had an outcome similar to patients with high-risk localized disease, and should be regarded as a separate category among patients with metastatic GIST.

Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience

“…These are also numerically higher than the 8‐ and 10‐year OS rate of 31% and 23% in the SWOG trial and 10‐year OS rate of 19.4% in the EORTC trial. Consistent with early imatinib trials and recent studies, the long‐term survivors of our study are characterized by younger age, smaller tumor size at the initiation of imatinib, and the presence of exon 11 mutation. Among 126 patients in period 1 with follow‐up >10 years, 42 patients (33.3%) were alive for more than 10 years at the time of the analysis.…”

“…Comparisons between early imatinib trials, recent studies (registered until 2010 or 2013), and the present study are summarized in Table . Although baseline demographic features and KIT or PDGFRA exon mutation were similar between studies, there were differences in tumor burden and surgical intervention.…”

Multimodal kreftbehandling av gastrointestinal stromal tumor

“…Imatinib ble godkjent som behandling for metastatisk gastrointestinal stromal tumor allerede i 2002. På Radiumhospitalet fikk den første pasienten med denne sykdommen imatinib i august 2001 (5). Medikamentet har senere vist seg å ha effekt også som tilleggsbehandling (adjuvant) etter operasjon for lokalisert gastrointestinal stromal tumor med høy risiko for tilbakefall (6).…”

“…Overlevelsen er betydelig forbedret etter innføring av imatinib og andre tyrosinkinasehemmere. Data fra Oslo universitetssykehus, Radiumhospitalet viser at median overlevelse har økt til syv år (5).…”

“…Pasientene responderer ofte raskt på behandlingen, og median varighet av respons er 2-3 år (3). Enkelte har levd i 10-15 år uten progrediering (5), men selv med langvarig behandlingseffekt regnes ikke pasientene som helbredet. Det er vist at nesten samtlige pasienter med metastatisk gastrointestinal stromal tumor som stopper med imatinib, får sykdomsprogrediering innen to år (15).…”